News

News Archive

New CELLSEARCH® Circulating Multiple Myeloma Test now available to help community physicians optimize patient care

New CELLSEARCH® Circulating Multiple Myeloma Test now available to help community physicians optimize patient care

As the market leader in cell-based liquid biopsies, Menarini Silicon Biosystems is offering community hematology-oncologists an opportunity to have patient blood samples sent to a US...
Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia

Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia

Florence (Italy) November 4th, 2021 – The Menarini Group announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for...

Select a Year from the Archive

Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Follow our blog

Discover our stories from all over the world

Read More